Accuracy
Measured against a reference set, failures included
Each cancer is checked against a reference set built by hand. A cancer is not called finished until all three checks below pass; until then it is shown here with its failures. The report is generated by the same code that grades trials on this site, not written by hand.
Adrenocortical carcinoma
Evaluated 2026-11-08 against a reference set dated 2026-10-07; 60 trials graded.
- PassA UK trial registered only on ISRCTN and EU CTIS (CLARITY) is found. ClinicalTrials.gov alone cannot answer this query.
- PassA profile with twelve lesions is never marked unmet on a lesion-count criterion where the protocol does not say whether it counts RECIST target lesions or total lesions; it is marked unknown with that question attached.
- FailA hand-built table of 11 listed and 5 ruled-out trials, written by a person over two expert days, is reproduced with matching grades.
Agreement with the reference table
Listed trials: 11 of 11. Ruled-out trials: 4 of 5.
Where it disagrees
- Cemiplimab maintenance (Brescia) (grade): expected not_eligible, got plausible.
Changed since the reference set was written
- Pembrolizumab in advanced ACC (Poland): now active not recruiting.